

Ketty Peris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4902811/publications.pdf>

Version: 2024-02-01

183
papers

4,990
citations

126907

33
h-index

133252

59
g-index

187
all docs

187
docs citations

187
times ranked

5655
citing authors

#	ARTICLE	IF	CITATIONS
1	A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1146-1149.	2.2	19
2	Novel MAPK/AKT-impairing germline NRAS variant identified in a melanoma-prone family. <i>Familial Cancer</i> , 2022, 21, 347-355.	1.9	1
3	Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care. <i>Italian Journal of Dermatology and Venereology</i> , 2022, 157, .	0.2	2
4	A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	12
5	Pediatric Hidradenitis Suppurativa: A Cross-Sectional Study on Clinical Features and Treatment Approaches. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, 26, 127-134.	1.2	7
6	Therapeutic Impact and Management of Persistent Head and Neck Atopic Dermatitis in Dupilumab-Treated Patients. <i>Dermatology</i> , 2022, 238, 717-724.	2.1	8
7	Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy. <i>Dermatitis</i> , 2022, 33, e25-e29.	1.6	2
8	Therapeutic potential of targeting interleukin-1 family cytokines in chronic inflammatory skin diseases*. <i>British Journal of Dermatology</i> , 2022, 186, 925-941.	1.5	29
9	Dermatoscopic and confocal microscopy features of widespread inflammatory linear verrucous epidermal nevus. <i>Italian Journal of Dermatology and Venereology</i> , 2022, 157, .	0.2	0
10	Severe and resistant palmar psoriasis successfully treated with risankizumab. <i>Italian Journal of Dermatology and Venereology</i> , 2022, 157, .	0.2	2
11	Flares as dynamic predictive factor of response to adalimumab in hidradenitis suppurativa: real-life data. <i>Italian Journal of Dermatology and Venereology</i> , 2022, 157, .	0.2	2
12	Biological agents targeting interleukin-13 for atopic dermatitis. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 651-659.	3.1	8
13	A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 339-352.	6.7	18
14	Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study. <i>Dermatologic Therapy</i> , 2022, 35, e15489.	1.7	13
15	Treatment approaches of advanced cutaneous squamous cell carcinoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 19-22.	2.4	10
16	European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force "Dermatology for cancer patients"™ position statement. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 332-350.	2.4	36
17	Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1292-1299.	2.4	23
18	Self-Assessment Questionnaire on Patient-Physician Concordance on Nevus Self-Count and Models Development to Predict High-Risk Phenotype >50 Nevi. <i>Dermatology</i> , 2022, 238, 986-995.	2.1	0

#	ARTICLE	IF	CITATIONS
19	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. <i>European Journal of Cancer</i> , 2022, 170, 236-255.	2.8	102
20	The role of stereotactic radiotherapy in addition to immunotherapy in the management of melanoma brain metastases: results of a systematic review. <i>Radiologia Medica</i> , 2022, 127, 773-783.	7.7	16
21	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 3741-3749.	1.6	33
22	Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1585-1592.	3.1	5
23	Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 347-355.	3.3	10
24	Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2021, 32, 507-513.	2.2	67
25	Evidence for a "window of opportunity"™ in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study*. <i>British Journal of Dermatology</i> , 2021, 184, 133-140.	1.5	88
26	Frailty screening in dermatology practice: a modified Delphi study and a systematic review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 95-104.	2.4	12
27	Reflectance confocal microscopy and its role in the follow-up of a topical treatment for lentigo maligna. <i>International Journal of Dermatology</i> , 2021, 60, 196-200.	1.0	3
28	Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)*. <i>British Journal of Dermatology</i> , 2021, 184, 437-449.	1.5	289
29	Recalcitrant Sweet Syndrome successfully treated with adalimumab. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 122-124.	0.8	6
30	Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 279-286.	3.1	12
31	Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1310-1320.	1.2	48
32	Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 958-964.	2.4	66
33	Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1119-1132.	2.4	5
34	A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e169-e170.	2.4	31
35	Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy. <i>Dermatology</i> , 2021, 237, 535-541.	2.1	18
36	Real-Time Confocal Imaging for Hidradenitis Suppurativa: Description of Morphological Aspects and Focus on the Role of Follicular Ostia. <i>Dermatology</i> , 2021, 237, 705-711.	2.1	4

#	ARTICLE	IF	CITATIONS
37	Purple papules during anti-PD1 immunotherapy for metastatic melanoma. JDDG - Journal of the German Society of Dermatology, 2021, 19, 630-632.	0.8	2
38	“Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management. Human Vaccines and Immunotherapeutics, 2021, , 1-8.	3.3	5
39	Pruritus as a Distinctive Feature of Type 2 Inflammation. Vaccines, 2021, 9, 303.	4.4	66
40	Position statement of the EADV Melanoma Task Force on recommendations for the management of cutaneous melanoma patients during COVID-19. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e427-e428.	2.4	14
41	Adverse cutaneous and mucous reactions from anti SARS-CoV-2 vaccines: recommendations from the Italian Society of Dermatology (SIDeMaST). Italian Journal of Dermatology and Venereology, 2021, 156, 115-117.	0.2	6
42	SARS-CoV-2 vaccines and biological treatments: dermatological perspectives. Italian Journal of Dermatology and Venereology, 2021, 156, 118-120.	0.2	3
43	Commentary to Shetty A, Janda M, Fry K et al. Clinical utility of skin cancer and melanoma risk scores for population screening: TRoPICS study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1244-1245.	2.4	0
44	The clinical spectrum of COVID-19-associated cutaneous manifestations: An Italian multicenter study of 200 adult patients. Journal of the American Academy of Dermatology, 2021, 84, 1356-1363.	1.2	61
45	Molecular alterations in basal cell carcinoma subtypes. Scientific Reports, 2021, 11, 13206.	3.3	19
46	Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. Expert Opinion on Biological Therapy, 2021, 21, 1299-1310.	3.1	19
47	Morphea-like changes in the setting of cancer immunotherapy. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e684-e685.	2.4	3
48	Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE AD7 Phase 3 randomized trial. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1543-1552.	2.4	41
49	Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia. Genetics in Medicine, 2021, 23, 2087-2095.	2.4	19
50	Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy. Expert Opinion on Biological Therapy, 2021, 21, 1291-1298.	3.1	5
51	Sonidegib after vismodegib discontinuation in a patient with Gorlin-Goltz syndrome and multiple basal cell carcinomas. Dermatologic Therapy, 2021, 34, e15095.	1.7	7
52	Clinical determinants of complete response to vismodegib in locally advanced basal cell carcinoma: a multicentre experience. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e923-e926.	2.4	2
53	Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2149-2153.	2.4	14
54	Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1949-1956.	2.4	10

#	ARTICLE	IF	CITATIONS
55	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. <i>European Journal of Cancer</i> , 2021, 157, 250-258.	2.8	52
56	Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. <i>Dermatology and Therapy</i> , 2021, 11, 235-252.	3.0	34
57	Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab. <i>Italian Journal of Dermatology and Venereology</i> , 2021, , .	0.2	4
58	Diagnosis and management of moderate to severe atopic dermatitis in adolescents. A Consensus by the Italian Society of Dermatology and Venereology (SIDEmaST), the Italian Association of Hospital Dermatologists and Public Health (ADOI), the Italian Association of Hospital and Territorial Allergists and Immunologists (AAIITO), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), the Italian Society of Pediatric Allergy and Immunology (SIAIP), the Italian Society of Allergological, Occupati. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 184-197.	0.2	9
59	Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 2551-2562.	1.8	3
60	Cold-Induced Urticaria in Children. <i>Skinmed</i> , 2021, 19, 339-348.	0.0	0
61	Treatments of actinic cheilitis: A systematic review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 876-887.	1.2	25
62	Adjuvant therapy for cutaneous melanoma: a systematic review and network meta-analysis of new therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 956-966.	2.4	19
63	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 159-177.	2.8	154
64	Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 932-941.	2.4	33
65	Response to: Comment on “Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines”™. <i>European Journal of Cancer</i> , 2020, 140, 154-157.	2.8	1
66	The Safety of Radiotherapy in the Treatment of Primary Cutaneous B-Cell Lymphoma: A Multidisciplinary Systematic Review. <i>Frontiers in Oncology</i> , 2020, 10, 1133.	2.8	1
67	The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV – UEMS and EORTC Cutaneous Lymphoma Task Force. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2183-2197.	2.4	22
68	The presence of eccentric hyperpigmentation should raise the suspicion of melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2802-2808.	2.4	2
69	Treatment monitoring of 5-fluorouracil 0.5%/salicylic acid 10% lesion-directed therapy for actinic keratosis using dermoscopy and in vivo reflectance confocal microscopy. <i>Dermatologic Therapy</i> , 2020, 33, e13744.	1.7	2
70	Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis. <i>Dermatology</i> , 2020, 236, 329-335.	2.1	9
71	Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study. <i>Future Oncology</i> , 2020, 16, 1091-1100.	2.4	3
72	Likelihood of finding melanoma when removing a melanocytic lesion with peripheral clods. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e812-e814.	2.4	6

#	ARTICLE	IF	CITATIONS
73	Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 39-45.	1.2	51
74	Italian expert consensus paper on the management of patients with actinic keratoses. <i>Dermatologic Therapy</i> , 2020, 33, e13992.	1.7	12
75	Reflectance Confocal Microscopy Applied to Folliculitis Decalvans: Preliminary Results of a Multicenter Study. <i>Skin Appendage Disorders</i> , 2020, 6, 202-206.	1.0	2
76	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. <i>European Journal of Cancer</i> , 2020, 128, 60-82.	2.8	131
77	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. <i>European Journal of Cancer</i> , 2020, 128, 83-102.	2.8	181
78	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 141-158.	2.8	133
79	One case of anetoderma post-vitamin K 1 injection in a newborn. <i>International Journal of Dermatology</i> , 2020, 59, e168-e169.	1.0	2
80	Jellyfish Sting – In Vivo Imaging for Diagnosis and Treatment Monitoring. <i>JAMA Dermatology</i> , 2020, 156, 348.	4.1	2
81	Comment on “Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines”™. <i>European Journal of Cancer</i> , 2020, 131, 100-103.	2.8	4
82	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. <i>Nature Genetics</i> , 2020, 52, 494-504.	21.4	138
83	Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa. <i>JAMA Dermatology</i> , 2020, 156, 708.	4.1	11
84	Non-Melanoma Skin Cancer in Outdoor Workers: A Study on Actinic Keratosis in Italian Navy Personnel. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2321.	2.6	11
85	Coding and noncoding somatic mutations in candidate genes in basal cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 8005.	3.3	17
86	Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 665-672.	3.1	49
87	Hidradenitis suppurativa and adalimumab in the COVID-19 era. <i>European Journal of Dermatology</i> , 2020, 30, 748-749.	0.6	9
88	Lentigo maligna: diagnosis and treatment. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 179-189.	0.8	2
89	A case of chronic disseminated lupus erythematosus in a psoriatic patient receiving ustekinumab. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 699-701.	0.8	2
90	Characterization of comorbid conditions burdening hidradenitis suppurativa: a multicentric observational study. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 335-340.	0.8	8

#	ARTICLE	IF	CITATIONS
91	Management of cutaneous melanoma: comparison of the leading international guidelines updated to the 8th American Joint Committee on Cancer staging system and workup proposal by the Italian Society of Dermatology. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 126-145.	0.8	5
92	New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 411-420.	0.8	8
93	Back to work from the lockdown: recommendations from the Italian Society of Dermatology (SIDeMaST) and the Italian Forensic Dermatologic Society (SIDeLF). <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 381-383.	0.8	2
94	5-Aminolaevulinic acid patch photodynamic therapy for the treatment of actinic keratoses: preliminary results from an Italian study in the real-life setting. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 636-641.	0.8	4
95	Physicianâ€ patient communication and patientâ€reported outcomes in the actinic keratosis treatment adherence initiative (<scp>AK</scp>â€<scp>TRAIN</scp>): a multicenter, prospective, realâ€life study of treatment satisfaction, quality of life and adherence to topical fieldâ€directed therapy for the treatment of actinic keratosis in Italy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 93-107.	2.4	16
96	Post-bariatric surgery hidradenitis suppurativa: a new patient subset associated with malabsorption and micronutritional deficiencies. <i>Clinical and Experimental Dermatology</i> , 2019, 44, 283-289.	1.3	14
97	Dietary compounds as potential modulators of microRNA expression in psoriasis. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231986480.	2.5	63
98	Diagnosis and treatment of basal cell carcinoma: European consensusâ€based interdisciplinary guidelines. <i>European Journal of Cancer</i> , 2019, 118, 10-34.	2.8	345
99	Efficacy and safety of Vismodegib treatment in patients with advanced basal cell carcinoma and multiple comorbidities. <i>Dermatologic Therapy</i> , 2019, 32, e13108.	1.7	8
100	Contribution of Common Genetic Variants to Familial Aggregation of Disease and Implications for Sequencing Studies. <i>PLoS Genetics</i> , 2019, 15, e1008490.	3.5	8
101	Age and gender influence on HIDRA-disk outcomes in adalimumabâ€treated hidradenitis suppurativa patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 25-27.	2.4	7
102	A familial case of Dowlingâ€Degos disease on the vulva. <i>Clinical and Experimental Dermatology</i> , 2019, 44, 921-923.	1.3	5
103	PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231984705.	2.5	4
104	A case of guttate psoriasis during treatment with dupilumab. <i>Dermatologic Therapy</i> , 2019, 32, e12998.	1.7	22
105	<p>Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential</p>. <i>Psoriasis: Targets and Therapy</i> , 2019, Volume 9, 29-35.	2.2	9
106	Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). <i>European Journal of Cancer</i> , 2019, 114, 117-127.	2.8	120
107	A rare case of bullous Sweet's syndrome in a patient with inactive ulcerative colitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e380-e381.	2.4	6
108	Ibrutinibâ€associated palmoâ€plantar fissures in a patient with Chronic Lymphocytic Leukaemia: a novel cutaneous adverse event. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e342-e344.	2.4	5

#	ARTICLE	IF	CITATIONS
109	Dermoscopic similarity is an independent predictor of <i>BRAF</i> mutational concordance in multiple melanomas. <i>Experimental Dermatology</i> , 2019, 28, 829-835.	2.9	4
110	Telomeres and Telomerase in Cutaneous Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1333.	4.1	13
111	Sunbed use legislation in Europe: assessment of current status. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 89-96.	2.4	10
112	Association of sunbed use with skin cancer risk factors in Europe: an investigation within the Euromelanoma skin cancer prevention campaign. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 76-88.	2.4	15
113	Prevalence and determinants of sunbed use in thirty European countries: data from the Euromelanoma skin cancer prevention campaign. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 13-27.	2.4	34
114	“Eternal sunshine of the spotless islands”: how dermoscopy may influence confocal microscopy when dealing with squamous cells carcinoma simulating basal cell carcinoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e277-e280.	2.4	2
115	Annular elastolytic giant cell granuloma following herpes zoster infection. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e334-e335.	2.4	0
116	Inherited non-alcoholic fatty liver disease and dyslipidemia due to monoallelic ABHD5 mutations. <i>Journal of Hepatology</i> , 2019, 71, 366-370.	3.7	41
117	Multiple paradoxical reactions during ixekizumab therapy. <i>Dermatologic Therapy</i> , 2019, 32, e12852.	1.7	9
118	Sclerosing nevus with pseudomelanomatous features: dermoscopic and confocal aspects. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 525-532.	2.4	2
119	Prevalence of cutaneous comorbidities in psoriatic patients and their impact on quality of life. <i>European Journal of Dermatology</i> , 2019, 29, 192-196.	0.6	9
120	Basal cell carcinoma: the utility of <i>in vivo</i> and <i>ex vivo</i> confocal microscopy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2090-2096.	2.4	22
121	Childhood trauma and resilience in psoriatic patients: A preliminary report. <i>Journal of Psychosomatic Research</i> , 2018, 106, 25-28.	2.6	21
122	Hidradenitis Suppurativa Associated with Down Syndrome Is Characterized by Early Age at Diagnosis. <i>Dermatology</i> , 2018, 234, 66-70.	2.1	24
123	Defining the actinic keratosis field: a literature review and discussion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 544-563.	2.4	54
124	Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 110-122.	2.8	22
125	Cutaneous melanoma in Birt-Hogg-Dubé syndrome: part of the clinical spectrum?. <i>British Journal of Dermatology</i> , 2018, 178, e132-e133.	1.5	13
126	Consensus on the management of patients with psoriatic arthritis in a dermatology setting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 515-528.	2.4	15

#	ARTICLE	IF	CITATIONS
127	Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls. <i>Genome Medicine</i> , 2018, 10, 99.	8.2	15
128	Alexithymia affects patients with hidradenitis suppurativa. <i>European Journal of Dermatology</i> , 2018, 28, 482-487.	0.6	13
129	Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. <i>European Journal of Cancer</i> , 2018, 104, 201-209.	2.8	37
130	Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 727-735.	3.1	52
131	Psoriasis Area and Severity Index response in moderate-to-severe psoriatic patients switched to adalimumab: results from the <scp>OPPSA</scp> study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1737-1744.	2.4	16
132	Use of reflectance confocal microscopy to diagnose occult basal cell carcinoma: 2 case reports. <i>JAAD Case Reports</i> , 2018, 4, 599-601.	0.8	1
133	Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma. <i>Human Molecular Genetics</i> , 2018, 27, 4145-4156.	2.9	34
134	Cutaneous squamous cell carcinoma. Italian Guidelines by SIDeMaST adapted to and updating EADO/EDF/EORTC guidelines. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2018, 153, 747-762.	0.8	22
135	MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortium. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2134-2141.	2.4	9
136	Clinico-dermoscopic features of alopecia areata in patients with psoriasis. <i>JAAD Case Reports</i> , 2018, 4, 665-668.	0.8	3
137	A new dermoscopic algorithm for the differential diagnosis of facial lentigo maligna and pigmented actinic keratosis. <i>European Journal of Dermatology</i> , 2018, 28, 162-168.	0.6	19
138	Antihypertensive drugs and risk of skin cancer. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2018, 153, 672-684.	0.8	8
139	Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 333-337.	0.2	2
140	A strange perianal ulcer. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2018, 153, 738-740.	0.8	0
141	Melanoma and tattoos: a case report and review of the literature. <i>European Journal of Dermatology</i> , 2018, 28, 50-55.	0.6	13
142	Lichen sclerosus of the glans simulating melanoma. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, S49-S51.	1.2	8
143	More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. <i>European Journal of Cancer</i> , 2017, 75, 313-322.	2.8	32
144	Untreated Psoriasis Impairs Male Fertility: A Case-Control Study. <i>Dermatology</i> , 2017, 233, 170-174.	2.1	32

#	ARTICLE	IF	CITATIONS
145	Role of personalized medication training in improving efficacy and adherence to a topical therapy in psoriatic patients. <i>Journal of Dermatological Treatment</i> , 2017, 28, 722-725.	2.2	15
146	Propofol-induced irreversible hair depigmentation: a case report. <i>International Journal of Dermatology</i> , 2017, 56, 676-678.	1.0	3
147	Long-term efficacy and safety of daylight photodynamic therapy with methyl aminolevulinic acid for actinic keratosis of the face and scalp. <i>European Journal of Dermatology</i> , 2017, 27, 89-91.	0.6	12
148	Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis. <i>Journal of Dermatological Treatment</i> , 2017, 28, 299-303.	2.2	16
149	Treatment of severe psoriasis in children: recommendations of an Italian expert group. <i>European Journal of Pediatrics</i> , 2017, 176, 1339-1354.	2.7	58
150	Linagliptin-induced bullous pemphigoid. <i>International Journal of Dermatology</i> , 2017, 56, 1467-1469.	1.0	10
151	Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. <i>Journal of Dermatological Treatment</i> , 2017, 28, 431-442.	2.2	76
152	Dermoscopy of small-size basal cell carcinoma: a case-control study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e273-e274.	2.4	9
153	Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics. <i>European Journal of Dermatology</i> , 2017, 27, 599-608.	0.6	30
154	Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric Oncology. , 2017, 8, 643.		146
155	Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments. <i>PLoS ONE</i> , 2017, 12, e0183415.	2.5	27
156	Practical indications for the management of non-melanoma skin cancer patients. <i>Italian Journal of Dermatology and Venereology</i> , 2017, 152, 286-294.	0.2	5
157	Linear and Bilateral Multinucleated Cell Angiohistiocytoma (MCAH). <i>Journal of Dermatological Case Reports</i> , 2017, 10, 58-61.	1.1	2
158	Management of local skin reactions after the application of ingenol mebutate gel for the treatment of actinic keratosis: four illustrative cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 320-321.	2.4	12
159	Italian expert consensus for the management of actinic keratosis in immunocompetent patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1077-1084.	2.4	41
160	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline "Update 2016. <i>European Journal of Cancer</i> , 2016, 63, 201-217.	2.8	330
161	Clinical predictors of nonresponse to anti-TNF- α agents in psoriatic patients: A retrospective study. <i>Dermatologic Therapy</i> , 2016, 29, 372-376.	1.7	21
162	Drug-induced hair colour changes. <i>European Journal of Dermatology</i> , 2016, 26, 531-536.	0.6	37

#	ARTICLE	IF	CITATIONS
163	Real-life efficacy and safety of ingenol mebutate for the treatment of actinic keratosis of the face and scalp: A single arm retrospective study. <i>Journal of Dermatological Treatment</i> , 2016, 27, 525-530.	2.2	11
164	Paradigmatic cases of pigmented lesions: How to not miss melanoma. <i>Journal of Dermatology</i> , 2016, 43, 1433-1437.	1.2	16
165	Brown globules in lentigo maligna (LM): A useful dermoscopic clue. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 429-430.	1.2	9
166	Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports. <i>Journal of International Medical Research</i> , 2016, 44, 67-71.	1.0	18
167	Adherence to topical therapies in actinic keratosis: A literature review. <i>Journal of Dermatological Treatment</i> , 2016, 27, 538-545.	2.2	14
168	Imiquimod 3.75% in actinic keratosis: efficacy in patients with and without rest periods during treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1416-1417.	2.4	10
169	Clinical, histopathological, and immunological evaluation of a series of patients with erythema nodosum. <i>International Journal of Dermatology</i> , 2016, 55, e289-94.	1.0	28
170	Melanoma and non-melanoma skin cancer in psoriatic patients treated with high-dose phototherapy. <i>Journal of Dermatological Treatment</i> , 2016, 27, 443-447.	2.2	36
171	Occurrence of hidradenitis suppurativa and phrynodema after bariatric surgery. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1215-1217.	2.4	3
172	Conventional Treatment of Actinic Keratosis: An Overview. <i>Current Problems in Dermatology</i> , 2015, 46, 108-114.	0.7	8
173	A randomized trial comparing simultaneous vs. sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2192-2198.	2.4	18
174	Efficacy of imiquimod 3.75% from Lmax according to the number of actinic keratosis lesions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2470-2473.	2.4	10
175	Association of psoriasis and/or psoriatic arthritis with autoimmune diseases: the experience of two Italian integrated Dermatology/Rheumatology outpatient clinics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2160-2168.	2.4	13
176	Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. <i>Future Oncology</i> , 2015, 11, 703-712.	2.4	35
177	Photodynamic therapy for basal cell carcinoma. <i>Future Oncology</i> , 2015, 11, 2991-2996.	2.4	25
178	Dermoscopic variability of basal cell carcinoma according to clinical type and anatomic location. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1732-1741.	2.4	53
179	Conventional vs. daylight methyl aminolevulinic photodynamic therapy for actinic keratosis of the face and scalp: an intra-patient, prospective, comparison study in Italy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1926-1932.	2.4	59
180	Human leukocyte antigen*58:01 allele in a familial case of Stevens-Johnson syndrome induced by allopurinol. <i>Journal of Dermatology</i> , 2015, 42, 753-754.	1.2	2

#	ARTICLE	IF	CITATIONS
181	Rationale for the Development of Speckled Hyperpigmentation in the Areas of Psoriatic Plaques after Treatment with Biologic Agents. Journal of Investigative Dermatology, 2015, 135, 318-320.	0.7	13
182	Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1840-1842.	2.4	8
183	Physician perceptions and experience of current treatment in actinic keratosis. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 298-306.	2.4	23